Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reticulocalbin-1 (RCN1) is an endoplasmic reticulum-resident calcium-binding protein from the CREC family, distinguished by six EF-hand domains and an HDEL ER retention signal. RCN1 regulates intracellular calcium homeostasis, modulates the unfolded protein response during ER stress, and inhibits stress-induced apoptosis through direct interaction with the inositol 1,4,5-trisphosphate receptor 1 (IP3R1). It also operates as a microglial phagocytosis ligand, facilitating the clearance of apoptotic cells, and is linked to cell proliferation and tumor progression, notably in oral, breast, and colorectal cancers. RCN1 expression in the plasma membrane is increased under certain stimuli, such as tumor necrosis factor alpha, and aberrant RCN1 expression or deletion affects development and disease, making it a possible biomarker and therapeutic target.
Suppression of ER stress-induced apoptosis via inhibition of ER calcium release and regulation of UPR signaling, specifically PERK- and IRE1-mediated pathways. Facilitates microglial phagocytosis by serving as a ligand for apoptotic cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reticulocalbin-1 (RCN1).